

"APRIL SHOWERS... BRING SALE FLOWERS!"

PRESENTING
A SPRING SEMINAR WITH
MATT WOOD, AIFD
TUESDAY, APRIL 21, 7-9 PM
\$15 PER PERSON
RESERVATIONS REQUIRED



Internationally known floral designer, consultant and educator, Matt shares his expertise for vibrant floral designs and "how to" ideas using clear resins and stunning silk florals.

40% OFF
all silk flowers April 1-30

684-2790
Park 217 Business Center
Tigard



A Gallery of Gifts
for Your Home

never on the fence when it comes to criminal defense

Emily Simon & Associates

Out with Clout

Emily Simon and Tracey Cordes, proud members of our community specializing in criminal defense.

Misdemeanor felony, traffic, & DUI actions in state, federal, & juvenile courts civil forfeitures, & administrative actions

(503) 241-1553

NATIONAL news

TRYING TIMES

The Portland area is one of the sites for an AmFAR clinical study of combination drug therapy for hepatitis C and HIV by Bob Roehr

The American Foundation for AIDS Research has begun recruitment for the first clinical trial of combination therapy for hepatitis C among those who are also HIV-positive. The 18-month study will involve 200 patients at 20 sites around the nation, including Portland.

Protease combination therapy has dramatically beaten back HIV for many, but that success has allowed time for more slowly developing medical conditions, such as hepatitis C, to emerge.

This second viral infection attacks the liver, scarring it and reducing liver function over the course of decades. Liver damage can make it harder to metabolize certain drugs, including protease inhibitors. It can ultimately lead to complete liver failure and death.

Some people living with HIV/AIDS who carry hepatitis C may not even know they have it. Until recently there was little effective therapy, so many doctors didn't even bother to screen for the hepatitis C virus. Furthermore, the standard screening test misses as many as half of the hepatitis C cases among those with HIV.

Many people with hepatitis C were infected through tainted blood products utilized prior to a screening program initiated in 1990.

Today, new infections are likely to come through sharing needles, cocaine straws, and blood during rough sex. Condoms offer protection, and the risk via oral sex is believed to be very small.

Interferon alpha is currently the only federal Food and Drug Administration-approved therapy for hepatitis C. It brings sustained viral repression in only 20 percent of those who complete the regimen.

A combination adding the synthetic nucleoside ribavirin seems to suppress the virus in

about 50 percent of cases. The combination has been submitted to the FDA for market approval.

So far, none of the trials of interferon and ribavirin have dealt with HIV-positive people. But anecdotal evidence suggests disease progression and reaction to treatment will be similar whether one is infected only with hepatitis C virus or coinfecting with HIV.

AmFAR brought physicians participating in the clinical trial to a day-long briefing in New York City on April 1.

The 18-month study involves 48 weeks of double-blind, placebo-controlled treatment in which half the subjects will receive interferon and ribavirin, and the other half will receive interferon and a placebo, explained Kevin Frost, director of clinical research for AmFAR.

The trial will measure hepatitis C viral load at several points during the regimen, as well as six months after it is completed, to see if there is sustained viral suppression.

Volunteers must have any HIV drug regimen stabilized at least four weeks prior to beginning this trial. Part of the initial screening process is a liver biopsy—a potentially painful procedure—to determine what, if any, liver scarring is present.

Participants will be taught to inject interferon under their skin, much as a diabetic does with insulin. Injections will be administered at least three times a week, or perhaps daily, for the duration of the trial.

Side effects of interferon range from very mild to severe flu-like symptoms and are often dose-related. Ribavirin is a pill with generally mild side effects. Both can cause anemia and loss of blood platelets.

For further information about the trial, contact Norma Martinez of the Portland-based Research & Education Group at 229-8428.



Protease combination therapy has dramatically beaten back HIV for many, but that success has allowed time for more slowly developing medical conditions, such as hepatitis C, to emerge.

You work hard to get to the top

so you can enjoy

coasting

down the

other

side.



Call 503-5002 for more information about our spas and the exceptional level of service that accompanies each one. Life has rewards. We've got one of them.

Oregon HotSpring Spas
Life has rewards.

Locations in Clackamas, Beaverton, Salem & Bend.

Call Today Choose Your Home

\$500 Down O.A.C.

(Some downpayments slightly higher)

Many more spaces available

**ATTN: Renters
1st Time Buyers**

SE PORTLAND Approx. 1380 sq. ft. 3 BD/2 BA FAMILY RM. \$745 Down \$611 Month O.A.C.	CLACKAMAS \$500 Down 3 BD/2 BA Private Beach Access	TROUTDALE 3 BD/2 BA \$500 Down \$480 Month O.A.C.	NEWBERG, SHERWOOD, TUALATIN, BEAVERTON Your Choice \$500 Down O.A.C.	HOOD RIVER OWN YOUR OWN LAND W/VIEW OF Mt. Hood	MILWAUKIE \$50,000 Call Today
---	---	---	---	---	--



Payments based on 30 years, 11.50% APR O.A.C.

659-7241

13233 S.E. McLoughlin, Milwaukie, OR

OR TOLL FREE 1-800-874-7030